Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal...

Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma ( Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA )

Expert commentary on emerging research in genitourinary cancer

Dr Chris Parker - The Royal Marsden Hospital, London, UK

Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )

VEGF targeted therapy and chemo an active combination in rapidly progressive...

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Tackling renal cancer with a combination of autologous immunotherapy and...

Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib ( Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA )

ASCO GU 2015: Prostate highlights from day one

Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin

ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )

Metastatic prostate cancer - Interpreting negative trial results

Prof Stephane Oudard and Prof Noel Clarke

Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma:...

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Are we doing all we can to manage adverse events?

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Are we doing all we can to manage adverse events? ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Real-world experience: achieving efficacy beyond clinical trials

Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA

mRCC: Real-world experience: achieving efficacy beyond clinical trials ( Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA )

mRCC: Understanding the patient's perspective

Dr David Cella - Northwestern University, Chicago, USA

mRCC: Understanding the patient's perspective ( Dr David Cella - Northwestern University, Chicago, USA )

mRCC: Closing remarks

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Closing remarks ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

Advances in haemato-oncology: Expert panel discussion

Prof Jesús San Miguel, Prof Umberto Vitolo, Prof Tim Illidge, Dr Francesc Bosch

Advances in haemato-oncology: Expert panel discussion ( Prof Jesús San Miguel, Prof Umberto Vitolo, Prof Tim Illidge, Dr Francesc Bosch )

More from ecancer